Trading Members of the Exchange are hereby informed that effective from Tuesday, May 9, 2023, the equity shares of Mankind Pharma Limited shall be listed and admitted to dealings on the Exchange in the list of 'B ' Group of Securities.
|
Name of the company
|
Mankind Pharma Limited
|
|
Registered Office:
|
208, Okhla Industrial Estate
Phase-III,New Delhi 110020, Delhi, India
Tel: +91 11 4747 6600
Email: investors@mankindpharma.com
Website: www.mankindpharma.com
|
|
No. of Securities
|
40,05,88,440 Equity Shares of Rs.1/- each fully paid up
|
|
Distinctive Number range
|
1 To 400588440
|
|
Scrip ID on BOLT System
|
MANKIND
|
|
Abbreviated Name on BOLT System
|
MANKIND
|
|
Scrip Code
|
543904
|
|
ISIN No.
|
INE634S01028
|
|
Market Lot
|
1
|
|
Issue Price for the current public issue
|
Rs. 1080/- per share (Face Value of Rs. 1/- and premium of Rs. 1079/-)
|
|
Date of Allotment in the public issue:
|
May 4, 2023
|
|
Pari Pasu
|
Yes
|
|
Financial Year
|
Mar-31
|
|
Lock in detail
|
As per Annexure I
|
|
Shareholding Pattern
|
As per Annexure II
|
a) Trading Members may note that as per the guidelines issued by SEBI dated 16th February, 2000, securities of the company will only be traded in Dematerialised form.
b) Further the trading members may please note that the above-mentioned scrip will be a part of Special Pre-open Session (SPOS) on Tuesday, May 9, 2023. For further information on SPOS, the trading members are requested to refer to the Exchanges notice no. 20120216-29 dated February 16, 2012 on Enabling Special Pre-open Session for IPOs & Relisted Scrips.
c) The company has informed the Exchange that in respect of shares in demat form, necessary corporate action has been executed to have the lock-in period marked in the depository’s records.
d) The Registrar to the issue as mentioned in the prospectus is given below
|
KFin Technologies Limited
Address: Selenium, Tower B, Plot No. 31 and 32 Financial District,
Nanakramguda, Serilingampally, Hyderabad
Rangareddi 500 032,Telangana, India
Tel: +91 40 6716 2222
E-mail: mankind.ipo@kfintech.com
Website: www.kfintech.com
Investor Grievance E-mail: einward.ris@kfintech.com
Contact Person: M Murali Krishna
SEBI Registration No: INR000000221
|
e) In case members require any clarifications on the subject matter of this notice, they may please contact any of the following:
|
a) At the company:
Pradeep Chugh
Company Secretary and Compliance Officer
|
Address:
208, Okhla Industrial Estate
Phase-III, New Delhi 110020, Delhi, India
Tel: +91 11 4747 6600
Email: investors@mankindpharma.com
Website: www.mankindpharma.com
|
|
b) At the Exchange:
Mr. Raghavendra Bhat
Associate Manager
|
Tel.: (91) 022 2272 8915
|
Rupal Khandelwal
Assistant General Manager
Monday, May 8,2023 |